DelveInsight’s “Chemotherapy Induced Neutropenia Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Chemotherapy Induced Neutropenia, historical and forecasted epidemiology as well as the Chemotherapy Induced Neutropenia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Chemotherapy Induced Neutropenia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chemotherapy Induced Neutropenia Market Forecast
Some of the key facts of the Chemotherapy Induced Neutropenia Market Report:
The Chemotherapy Induced Neutropenia market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
In November 2023, The US FDA approved Evive Biotech’s RYZNEUTA (efbemalenograstim alfa) for the treatment of chemotherapy-induced neutropenia.
In the seven major markets (7MM), the estimated total number of cancer patients receiving chemotherapy was approximately 1,817,000 in 2023.
In 2023, the US had the highest number of cancer patients receiving chemotherapy, accounting for approximately 706,000 cases in the seven major markets (7MM). Japan ranked second among the 7MM, with approximately 323,000 cancer patients undergoing chemotherapy in 2023.
In 2023, the UK had approximately 168,000 cancer patients undergoing chemotherapy. These figures are projected to rise further during the forecast period from 2024 to 2034.
DelveInsight assessments indicate that in Germany in 2023, there were approximately 148,000 cases classified as intermediate-high risk for cervical intraepithelial neoplasia (CIN), and around 64,000 cases classified as low risk for CIN.
Among the EU4 nations, Germany reported the highest number of cases of cervical intraepithelial neoplasia (CIN) with approximately 98,000 cases in 2023. Conversely, Spain had the lowest number of CIN cases in 2023, totaling around 47,000 cases.
Key Chemotherapy Induced Neutropenia Companies: Enzychem Lifesciences Corporation, Aileron Therapeutics, Evive Biotech, Myelo therapeutics, BeyondSpring Pharmaceuticals, BeyondSpring Pharmaceuticals, Dong-A ST Co., Ltd., Tianjin SinoBiotech Ltd., Biocad, Tianjin SinoBiotech Ltd., Teva Branded Pharma, Sandoz GmbH, Kyowa Kirin Co., Ltd., Prothya Biosolutions, and others
Key Chemotherapy Induced Neutropenia Therapies: EC-18, ALRN-6924, F-627 (Ryzneuta), Myelo001, Plinabulin, Pegfilgrastim, PEG-G-CSF, rHSA-GCSF 2.4mg, empegfilrastim, HSA-GCSF, Chemotherapy Regimen, LA-EP2006, pegfilgrastim, Mannan Binding Lectin (MBL), and others
The Chemotherapy Induced Neutropenia epidemiology based on gender analyzed that out of the total patients on chemotherapy, maximum patients are at intermediate-high risk for CIN
The Chemotherapy Induced Neutropenia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chemotherapy Induced Neutropenia pipeline products will significantly revolutionize the Chemotherapy Induced Neutropenia market dynamics.
Chemotherapy Induced Neutropenia Overview
For cancer patients receiving chemotherapy, the main dose-limiting hazard is chemotherapy-induced neutropenia (CIN). It is linked to higher morbidity and early mortality, higher medical expenses, and interruptions in potentially curative therapies. It can result in febrile neutropenia (FN).
Get a Free sample for the Chemotherapy Induced Neutropenia Market Report:
https://www.delveinsight.com/report-store/chemotherapy-induced-neutropenia-cin-market
Chemotherapy Induced Neutropenia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Chemotherapy Induced Neutropenia Epidemiology Segmentation:
The Chemotherapy Induced Neutropenia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Prevalence of Chemotherapy Induced Neutropenia
Prevalent Cases of Chemotherapy Induced Neutropenia by severity
Gender-specific Prevalence of Chemotherapy Induced Neutropenia
Diagnosed Cases of Episodic and Chronic Chemotherapy Induced Neutropenia
Download the report to understand which factors are driving Chemotherapy Induced Neutropenia epidemiology trends @ Chemotherapy Induced Neutropenia Epidemiology Forecast
Chemotherapy Induced Neutropenia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chemotherapy Induced Neutropenia market or expected to get launched during the study period. The analysis covers Chemotherapy Induced Neutropenia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Chemotherapy Induced Neutropenia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Chemotherapy Induced Neutropenia Therapies and Key Companies
EC-18: Enzychem Lifesciences Corporation
ALRN-6924: Aileron Therapeutics
F-627 (Ryzneuta): Evive Biotech
Myelo001: Myelo therapeutics
Plinabulin: BeyondSpring Pharmaceuticals
Pegfilgrastim: BeyondSpring Pharmaceuticals
PEG-G-CSF: Dong-A ST Co., Ltd.
rHSA-GCSF 2.4mg: Tianjin SinoBiotech Ltd.
empegfilrastim: Biocad
HSA-GCSF: Tianjin SinoBiotech Ltd.
Chemotherapy Regimen: Teva Branded Pharma
LA-EP2006: Sandoz GmbH
pegfilgrastim: Kyowa Kirin Co., Ltd.
Mannan Binding Lectin (MBL): Prothya Biosolutions
Discover more about therapies set to grab major Chemotherapy Induced Neutropenia market share @ Chemotherapy Induced Neutropenia Treatment Market
Chemotherapy Induced Neutropenia Market Strengths
The growth in the cancer patient population, along with a rise in the comorbidities and use of certain drugs (chemotherapies) over the globe, is contributing to the rise in the incidence of CIN
An increase in clinical trials activity for emerging therapies will boost the market
Rising awareness about the disease among clinicians and patients
Chemotherapy Induced Neutropenia Market Opportunities
Limited development in the mechanism of action of approved therapies in the market offers a great opportunity for the investment and development of emerging novel therapies
Medications with better safety for long term use and low treatment duration are the current unmet need of the CIN market
Low-cost therapies and therapies with good patient compliance might be the game-changer for the CIN treatment market
Scope of the Chemotherapy Induced Neutropenia Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Chemotherapy Induced Neutropenia Therapeutic Assessment: Chemotherapy Induced Neutropenia current marketed and Chemotherapy Induced Neutropenia emerging therapies
Chemotherapy Induced Neutropenia Market Dynamics: Chemotherapy Induced Neutropenia market drivers and Chemotherapy Induced Neutropenia market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Chemotherapy Induced Neutropenia Unmet Needs, KOL’s views, Analyst’s views, Chemotherapy Induced Neutropenia Market Access and Reimbursement
To know more about Chemotherapy Induced Neutropenia companies working in the treatment market, visit @ Chemotherapy Induced Neutropenia Clinical Trials and Therapeutic Assessment
Table of Contents
1. Chemotherapy Induced Neutropenia Market Report Introduction
2. Executive Summary for Chemotherapy Induced Neutropenia
3. SWOT analysis of Chemotherapy Induced Neutropenia
4. Chemotherapy Induced Neutropenia Patient Share (%) Overview at a Glance
5. Chemotherapy Induced Neutropenia Market Overview at a Glance
6. Chemotherapy Induced Neutropenia Disease Background and Overview
7. Chemotherapy Induced Neutropenia Epidemiology and Patient Population
8. Country-Specific Patient Population of Chemotherapy Induced Neutropenia
9. Chemotherapy Induced Neutropenia Current Treatment and Medical Practices
10. Chemotherapy Induced Neutropenia Unmet Needs
11. Chemotherapy Induced Neutropenia Emerging Therapies
12. Chemotherapy Induced Neutropenia Market Outlook
13. Country-Wise Chemotherapy Induced Neutropenia Market Analysis (2020–2034)
14. Chemotherapy Induced Neutropenia Market Access and Reimbursement of Therapies
15. Chemotherapy Induced Neutropenia Market Drivers
16. Chemotherapy Induced Neutropenia Market Barriers
17. Chemotherapy Induced Neutropenia Appendix
18. Chemotherapy Induced Neutropenia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
